|
| Status |
Public on Apr 03, 2013 |
| Title |
control replicate 3 |
| Sample type |
RNA |
| |
|
| Source name |
control
|
| Organism |
Mus musculus |
| Characteristics |
tumor type: Lymphoma
shRNA: Rluc.713
genotype/variation: Arf-/-Eu-myc/Bcl-2 lymphomas
|
| Treatment protocol |
Cells were transduced with either Rluc.713 or Dhx9.1241shRNA
|
| Growth protocol |
Lymphomas used in this study were maintained in B-cell Media (BCM; 45% DMEM, 45% Iscove’s Media, 55 mM b-mercaptoethanol, 10% Fetal Bovine Serum) on g-irradiated Arf-/- MEF feeder layers. Feeder layers were comprised of ~25% confluent irradiated Arf-/- MEFs pre-incubated with BCM for 3 days prior to addition of lymphoma cells. Lymphomas were routinely split 1:3 every 2-3 days and discarded after >3 weeks in culture.
|
| Extracted molecule |
total RNA |
| Extraction protocol |
Total RNA was extracted using trizol.
|
| Label |
biotin
|
| Label protocol |
The 3’ IVT Express Kit (Affymetrix) using conditions recommended by the manufacturer.
|
| |
|
| Hybridization protocol |
The resulting labeled samples were hybridized to the Affymetrix Mouse Gene 1.0 ST Array from Affymetrix according the instructions of the manufacturer
|
| Scan protocol |
Arrays were scanned using the GeneArray Scanner 3000 according to the instructions from the manufacturer.
|
| Description |
Arf-/-Eu-myc/Bcl-2 lymphomas with Rluc.713 shRNA replicate 3
|
| Data processing |
Data was extracted and normalized using a custom CDF and Robust Multi-array Average (RMA) in R (r-project.org) with default settings.
|
| |
|
| Submission date |
Mar 29, 2012 |
| Last update date |
Apr 03, 2013 |
| Contact name |
Ola Larsson |
| E-mail(s) |
ola.larsson@ki.se
|
| Phone |
+46 (0)8 517 73280
|
| Organization name |
Karolinska Institutet
|
| Department |
Department of oncology-pathology
|
| Street address |
CCK, R8:01
|
| City |
Stockholm |
| ZIP/Postal code |
171 76 |
| Country |
Sweden |
| |
|
| Platform ID |
GPL11078 |
| Series (1) |
| GSE36938 |
Engineering ABT-737 Resistance in MYC-driven Lymphomas Identifies DHX9 as a Drug Response Modifier |
|
